832 Variability in secretion of growth factors by platelets is intrinsic to alopecia patients undergoing platelet-rich plasma therapy

Background: The use of autologous platelet-rich plasma as an ovarian treatment has not been standardized and remains controversial. Case Presentation: A 41½-year old woman with diminished ovarian reserve (serum anti- Müllerian hormone = 0.163 mg/mL) and a history of 10 unsuccessful in vitro fertilization cycles presented for reproductive endocrinology consult. She and her partner declined donor oocyte in vitro fertilization. They were both in good general health and laboratory tests were unremarkable, except for mild thrombocytosis (platelets = 386K; normal range 150-379K) discovered in the female. The patient underwent intraovarian injection of fresh platelet-derived growth factor concentrate administered as an enriched cell-free substrate. Serum anti- Müllerian hormone increased by 115% within 6 wks of treatment. Spontaneous ovulation occurred the month after injection and subsequently the serum human chorionic gonadotropin was noted at 804 mIU/mL. Following an uneventful obstetrical course, a male infant was delivered at term without complication. Conclusion: This is the first description of intraovarian injection of enriched platelet-derived growth factors followed by unassisted pregnancy and live birth. As a refinement of conventional ovarian platelet-rich plasma therapy, this procedure may be particularly valuable for refractory cases where prognosis for pregnancy appears especially bleak. A putative role for thrombocytosis is also viewed in parallel with mechanisms of action as advanced earlier. With continued experience in ovarian application of autologous platelet growth factors, additional research will evaluate laboratory protocol/sample preparation, injection technique, and patient selection. Key words: Ovarian rejuvenation, Platelet-rich plasma, Cytokines, Infertility, IVF.

Download Full-text

A Study of the Efficacy of Skin Needling and Platelet Rich Plasma in the Treatment of Acne Scars

Nepal Journal of Dermatology Venereology & Leprology ◽

10.3126/njdvl.v15i1.18047 ◽

2017 ◽

Vol 15 (1) ◽

pp. 17-23

Author(s):

Shivani Ranjan ◽

RS Gupta ◽

S Gupta

Keyword(s):

Wound Healing ◽

Growth Factors ◽

Platelet Rich Plasma ◽

Monthly Interval ◽

P Value ◽

Collagen Deposition ◽

Acne Scar ◽

Plasma Therapy ◽

Acne Scars ◽

Combined Use

Introduction: Permanent scars are the major complications of acne. Correction of scars is the priority for acne patients. Platelet-rich plasma (PRP) may be useful in the treatment of atrophic acne scars by promoting collagen deposition. Skin needling also releases growth factors, initiate a cascade of wound healing resulting in collagen production. Hence, skin needling and PRP should act synergistically to improve acne scars.Objective: To assess the effectiveness of the combined use of skin needling and PRP application in acne scar treatment.Material and Methods: The study enrolled 10 patients of acne scars. Platelet rich plasma therapy with needling was given to them at monthly interval for a therapeutic period of 6 months. The effects of therapy were evaluated based on photographic assessment and patient’s satisfaction.Results: Mean age of the patients was 28.10 ± 5.065. Twenty percent of patients showed excellent response, 80% showed good response. The results were found to be significant with p value < 0.014. Pain and edema were major complaints which subsided in 1-2 days.Conclusion: Platelet rich plasma therapy combined with skin needling is a safe and effective treatment for management of acne scars.

Download Full-text

The “biological chamber” method – use of autologous platelet-rich plasma (PRP) in the treatment of poorly healing lower-leg ulcers of venous origin

Polish Journal of Surgery ◽

10.1515/pjs-2015-0055 ◽

2015 ◽

Vol 87 (6) ◽

Cited By ~ 2

Author(s):

Dariusz Waniczek ◽

Wojciech Mikusek ◽

Tomasz Kamiński ◽

Mariusz Wesecki ◽

Zbigniew Lorenc ◽

...

Keyword(s):

Growth Factors ◽

Chronic Wounds ◽

Platelet Rich Plasma ◽

Healing Process ◽

Lower Leg ◽

Complete Healing ◽

Leg Ulcers ◽

Plasma Therapy ◽

Autologous Platelet Rich Plasma ◽

Autologous Platelet

AbstractWound healing is a complex pathophysiological process, in which platelets play a crucial role. Platelet alpha-granules release growth factors to the wound bed; the factors are necessary in the healing process. In chronic wounds, such as poorly healing lower-leg ulcers of venous origin, there is decreased activity of multiple growth factors, so the concept of exogenous delivery of such factors seems a logical strategy. Platelet-rich plasma therapy in patients with lower-leg ulcers of venous origin combined with conventional treatment methods (previously ineffective in these patients) seems, based on our observation, an important adjunct leading to recovery.The aim of the study was to present an original method of autologous platelet-rich plasma application through the creation of a sort of “biological chamber” containing a concentrate of growth factors.Material and methods. The described therapy was implemented in 10 patients, who had been ineffectively treated for more than one year in the outpatient setting. Patients with exacerbation of inflammatory process, signs of wound infection and ankle brachial pressure index < 0.8 were excluded from the study. After the application of platelet-rich plasma, further treatment was continued with the use of moist therapy and compression therapy according to a uniform regimen.Results. Complete healing was achieved within 4-10 weeks from the beginning of the product administration in all patients.Conclusion. The presented method seems technically simple, effective and relatively inexpensive

Download Full-text

Advantages and Clinical Applications of Lyophilized Platelet-Rich Plasma in Various Disease Conditions: A Review

International Journal for Research in Applied Science and Engineering Technology ◽

10.22214/ijraset.2021.39092 ◽

2021 ◽

Vol 9 (11) ◽

pp. 1885-1892

Author(s):

Pradeep Mahajan

Keyword(s):

Growth Factors ◽

Platelet Rich Plasma ◽

Autologous Blood ◽

Healing Process ◽

Coagulation Factor ◽

The Body ◽

Plasma Therapy ◽

Plasma Fraction ◽

Wide Range ◽

Platelet Concentration

Abstract: Platelet rich plasma (PRP) is a biological product defined as a portion of the plasma fraction of autologous blood with a platelet concentration above the baseline. The plasma occupies 55% of blood, which is rich in immunoglobulins and proteins that have a wide range of applications in various medical fields. Plasma therapy is applied to tackle various disorders or diseases as it induces the body to develop new healthy cells. It contains important components like antibodies, coagulation factor, enzymes, fibrinogen, proteins and albumin. PRP is a unique and advanced treatment which helps to increases the body’s natural healing process. Platelet lysate which is obtained from platelet rich plasma consist of various growth factors such as chemokines, cytokines, and antibacterial molecules and also has anti-inflammatory, immunomodulatory, anti-fibrotic and repairing effects. As PRP is rich in the proteins and several antibodies, it is used for various chronic therapies such as hemophilia and autoimmune disorders as well as in various severe health problems. Lyophilized Platelet-rich plasma (LPRP) therapy is currently used in various fields such as in tissue regeneration, wound healing, scar revision, skin rejuvenating effects, alopecia and for the coronavirus disease (COVID-19). It is also used to heal wounds and illnesses. LPRP therapy is gaining attraction by many health professionals as it is a safe, effective, efficient, and easy approach in procuring, preserving, and therapy. In this review we described the advantages and applications of using lyophilized PRP in various diseases which might found to be effective in different treatment. Keywords: Plasma, Platelet, Growth Factors, Lyophilized platelet rich plasma.

Download Full-text

Use of PRP, PRF and CGF in Periodontal Regeneration and Facial Rejuvenation—A Narrative Review

Biology ◽

10.3390/biology10040317 ◽

2021 ◽

Vol 10 (4) ◽

pp. 317

Author(s):

Eitan Mijiritsky ◽

Haya Drora Assaf ◽

Oren Peleg ◽

Maayan Shacham ◽

Loredana Cerroni ◽

...

Keyword(s):

Growth Factors ◽

Platelet Rich Plasma ◽

Periodontal Regeneration ◽

Clinical Work ◽

Gingival Recession ◽

Vital Role ◽

Facial Rejuvenation ◽

Cochrane Library ◽

The Past ◽

Autologous Platelet

Growth factors (GFs) play a vital role in cell proliferation, migration, differentiation and angiogenesis. Autologous platelet concentrates (APCs) which contain high levels of GFs make them especially suitable for periodontal regeneration and facial rejuvenation. The main generations of APCs presented are platelet-rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) techniques. The purpose of this review is to provide the clinician with an overview of APCs’ evolution over the past decade in order to give reliable and useful information to be used in clinical work. This review summarizes the most interesting and novel articles published between 1997 and 2020. Electronic and manual searches were conducted in the following databases: Pubmed, Scopus, Cochrane Library and Embase. The following keywords were used: growth factors, VEGF, TGF-b1, PRP, PRF, CGF and periodontal regeneration and/or facial rejuvenation. A total of 73 articles were finally included. The review then addresses the uses of the three different techniques in the two disciplines, as well as the advantages and limitations of each technique. Overall, PRP is mainly used in cases of hard and soft tissue procedures, while PRF is used in gingival recession and the treatment of furcation and intrabony defects; CGF is mainly used in bone regeneration.

Download Full-text

Healing the Elite Athlete Today: Investigating the Case of Platelet-Rich Plasma Therapy

Sport Ethics and Philosophy ◽

10.1080/17511321.2021.1910995 ◽

2021 ◽

pp. 1-13

Author(s):

Yu Xuan Su

Keyword(s):

Elite Athlete ◽

Platelet Rich Plasma ◽

Plasma Therapy

Download Full-text

Response to “Enhancing Fat Graft Survival With Autologous Growth Factors: Platelet-Rich Fibrin (PRF) vs Platelet-Rich Plasma (PRP)”

Aesthetic Surgery Journal ◽

10.1093/asj/sjaa392 ◽

2021 ◽

Author(s):

Panxi Yu ◽

Xiaonan Yang ◽

Zuoliang Qi

Keyword(s):

Growth Factors ◽

Graft Survival ◽

Platelet Rich Plasma ◽

Fat Graft ◽

Platelet Rich Fibrin

Download Full-text

Clinical Efficacy of Platelet-Rich Plasma Injection and Its Association With Growth Factors in the Treatment of Mild to Moderate Knee Osteoarthritis: A Randomized Double-Blind Controlled Clinical Trial As Compared With Hyaluronic Acid

The American Journal of Sports Medicine ◽

10.1177/0363546520986867 ◽

2021 ◽

Vol 49 (2) ◽

pp. 487-496

Author(s):

Yong-Beom Park ◽

Jun-Ho Kim ◽

Chul-Won Ha ◽

Dong-Hyun Lee

Keyword(s):

Hyaluronic Acid ◽

Growth Factors ◽

Knee Osteoarthritis ◽

Clinical Outcomes ◽

Clinical Efficacy ◽

Global Assessment ◽

Platelet Rich Plasma ◽

Patient Global Assessment ◽

Symptomatic Knee Osteoarthritis ◽

Symptomatic Knee

Background: Although platelet-rich plasma (PRP) has potential as a regenerative treatment for knee osteoarthritis, its efficacy varies. Compositional differences among types of PRP could affect clinical outcomes, but the biological characterization of PRP is lacking. Purpose: To assess the efficacy of intra-articular PRP injection in knee osteoarthritis as compared with hyaluronic acid (HA) injection and to determine whether the clinical efficacy of PRP is associated with its biological characteristics. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: A total of 110 patients with symptomatic knee osteoarthritis received a single injection of leukocyte-rich PRP (1 commercial kit) or HA. Clinical data were assessed at baseline and at 6 weeks and 3 and 6 months after injection. The primary endpoint was an improvement in the International Knee Documentation Committee (IKDC) subjective score at 6 months, and the secondary endpoints were improvements in scores based on the Patient Global Assessment, the visual analog scale (VAS) for pain, the Western Ontario and McMaster Universities Osteoarthritis Index, and the Samsung Medical Center patellofemoral score. Cell counts and concentrations of growth factors and cytokines in the injected PRP were assessed to determine their association with clinical outcomes. Results: PRP showed significantly improvement in IKDC subjective scores at 6 months (11.5 in the PRP group vs 6.3 in the HA group; P = .029). There were no significant differences between groups in other clinical outcomes. The Patient Global Assessment score at 6 months was better in the PRP group ( P = .035). The proportion of patients who scored above the minimal clinically important difference (MCID) for VAS at 6 months was significantly higher in the PRP group ( P = .044). Within the PRP group, the concentrations of platelet-derived growth factors were high in patients with a score above the MCID for VAS at 6 months. The incidence of adverse events did not differ between the groups ( P > .05). Conclusion: PRP had better clinical efficacy than HA. High concentrations of growth factors were observed in patients who scored above the MCID for clinical outcomes in the PRP group. These findings indicate that concentration of growth factors needs to be taken into consideration for future investigations of PRP in knee osteoarthritis. Registration: NCT02211521 (ClinicalTrials.gov identifier).

Download Full-text